The Japanese Encephalitis virus (JEV) is a viral brain infection transmitted through mosquitoes’ bites1. It is the main cause of viral encephalitis in many countries of Asia. Although less likely to be symptomatic, the case-fatality rate among the cases can be as high as 30% (WHO). It is currently endemic in many asia countries and there is no cure. WHO recommends JE vaccine to be integrated into the national immunization schedule in affected countries.
Japanese Encephalitis Vaccine, Live Attenuated (because there is a live recombinant vaccine for JE) (this needs to be verified with CNBG) Over the past years, the live attenuated SA14-14-2 vaccine manufactured in China has become the most widely used vaccine in endemic countries (WHO). Our vaccine is approved by the World Health Organization (WHO) and is of International JE vaccine quality standard (WHO-TRS910).
The COVID-19 pandemic has underscored the importance of research and development in preparation for future pandemics. In Sino-Innovax, we focus on predicting new infectious landscapes and challenge the frontiers of vaccine science. We are open to collaboration with innovative and cutting-edge technologies and products which align with our strategic interest.
Plasma being the largest component in the human blood, helps individuals to stay healthy. Plasma-derived products are prepared from the separation of proteins in the human plasma and are vital in the treatment of autoimmune diseases. a. Human Immunoglobulin (pH4) for Intravenous Injection IVIG targets a wide range of autoimmune diseases […]
Our parent company China National Biotec Group (CNBG) is the 6th largest vaccine manufacturer in the world. CNBG has the capacity of manufacturing approximately 700 million doses of 50 various human vaccines (a year?) Sino-Innovax is also committed to benefit people from all around the globe through our constant development of efficient and novel vaccines. […]